X-ray crystallography will be used to determine high-resolution structures for cruzain, cruzain mutants, and their complexes with a variety of inhibitors and their derivatives. Our goal is to develop a therapeutic agent for Chagas' disease by inhibition of the major cysteine protease of Trypanosoma cruzi. Structure analysis will be used in conjunction with enzyme kinetics (Dr. Craik) and computational methods (Dr. Cohen) to find, test (Dr. Craik, Dr. McKerrow, Dr. Engel) and synthesize (Dr. Roush) tight-binding and highly-specific inhibitors for cruzain. To this end, we have recently solved the 2.35Angstroms X-ray structure of cruzain by molecular replacement methods. The structure will be refined to convergence and used as a model for computational methods including DOCK3.0 to begin the search for possible inhibitors. A higher resolution structure (2.0Angstroms or better) will be obtained and will provide a more accurate and informative model for the inhibitor search. Methods will be developed for crystallization of a wide variety of complexes between the cruzains and putative inhibitors. A panoply of structures will be determined, involving cruzain bound to different types of inhibitors and their derivatives, and cruzain mutants with inhibitors and substrates. This will provide a detailed map of the substrate binding site. Our in-depth analysis, in which binding at each subsite is carefully evaluated by site-directed mutagenesis, kinetic analyses, theoretical calculations including molecular dynamics simulations and correlations with atomic temperature factors, should yield an effective therapeutic for Chagas' disease as well as elucidating nuances of cysteine protease function.

Project Start
1998-05-01
Project End
1999-04-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Lee, Gregory M; Balouch, Eaman; Goetz, David H et al. (2012) Mapping inhibitor binding modes on an active cysteine protease via nuclear magnetic resonance spectroscopy. Biochemistry 51:10087-98
Doyle, Patricia S; Zhou, Yuan M; Hsieh, Ivy et al. (2011) The Trypanosoma cruzi protease cruzain mediates immune evasion. PLoS Pathog 7:e1002139
Boyom, Fabrice Fekam; Fokou, Patrick Valere Tsouh; Yamthe, Lauve Rachel Tchokouaha et al. (2011) Potent antiplasmodial extracts from Cameroonian Annonaceae. J Ethnopharmacol 134:717-24
Swenerton, Ryan K; Zhang, Shuyi; Sajid, Mohammed et al. (2011) The oligopeptidase B of Leishmania regulates parasite enolase and immune evasion. J Biol Chem 286:429-40
Robertson, Stephanie A; Renslo, Adam R (2011) Drug discovery for neglected tropical diseases at the Sandler Center. Future Med Chem 3:1279-88
Huang, Niu; Jacobson, Matthew P (2010) Binding-site assessment by virtual fragment screening. PLoS One 5:e10109
Chen, Yen Ting; Brinen, Linda S; Kerr, Iain D et al. (2010) In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi. PLoS Negl Trop Dis 4:
Chen, Chiung-Kuang; Leung, Siegfried S F; Guilbert, Christophe et al. (2010) Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole. PLoS Negl Trop Dis 4:e651
Brak, Katrien; Kerr, Iain D; Barrett, Kimberly T et al. (2010) Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas disease chemotherapy. J Med Chem 53:1763-73
Guiguemde, W Armand; Shelat, Anang A; Bouck, David et al. (2010) Chemical genetics of Plasmodium falciparum. Nature 465:311-5

Showing the most recent 10 out of 126 publications